Myriad Genetics new tech ups performance of prenatal test

Myriad Genetics (MYGN +0.5%) has launched its proprietary AMPLIFY technology, which further increases the performance of its Prequel noninvasive prenatal screening (NIPS) test.

The AMPLIFY process increases the fetal fraction of a NIPS sample by preferentially sequencing the fetal cell-free DNA fragments that circulate in a mother’s blood, enabling more accurate detection of fetal chromosome abnormalities.

The company says that in the analytical validation involving samples from more than 1,000 pregnant women, fetal fraction was 2.3 times greater on average with AMPLIFY, than with standard NIPS.

https://seekingalpha.com/news/3596753-myriad-geneticss-new-technology-improves-performance-of-prequel-nips

Multiple volatility halts on Kodak as it soars 450%

The president last night announced an agreement with Kodak (NYSE:KODK) for that company to produce generic drugs here in the U.S.

Shares more than tripled in the regular session on Tuesday after the WSJ reported on the deal – a $765M loan to help speed domestic production of drugs.

Shares are higher by 62% premarket to $12.86. They closed Friday at $2.62.

Update at 10:30 AM ET: Shares are now up 450% to $43.50 per share, already having blown through a number of volatility halts.

Appearing on CNBC this morning, CEO James Continenza says Kodak can be competitive in pharmaceuticals, noting it’s already got a factory with its own power, steam, waste recovery, and rail system. “The infrastructure is there. I’m not paying for that. Those are huge costs.”

https://seekingalpha.com/news/3596618-multiple-volatility-halts-on-kodak-soars-450-following-presidential-mention

Smith & Nephew beats on revenue

Smith & Nephew (NYSE:SNN): 1H Non-GAAP EPS of $0.13; GAAP EPS of $0.12.

Revenue of $2.04B (-18.1% Y/Y) beats by $160M.

Trading profit fell to $172M from $532M for the year-earlier period, with a margin of 8.5%.

Press Release

https://seekingalpha.com/news/3596451-smith-nephew-beats-on-revenue

Anthem EPS beats by $0.62, misses on revenue

Anthem (NYSE:ANTM): Q2 Non-GAAP EPS of $9.20 beats by $0.62; GAAP EPS of $8.91 beats by $0.05.

Revenue of $29.18B (+15.9% Y/Y) misses by $190M.

Total medical membership of 42.5M vs. estimate 41.3M.

Benefit expense ratio of 77.9% vs. consensus of 80.8%.

Press Release

https://seekingalpha.com/news/3596482-anthem-eps-beats-0_62-misses-on-revenue

Sanofi Q2 Dupixent sales up 70%; EPS guidance revised upward

Sanofi (SNY) Q2 results (€):

Revenues: 8,207M (-4.9%); Pharmaceuticals: 6,256M (-3.1%); Consumer Healthcare: 1,024M (-10.8%); Vaccines: 927M (-9.2%).

Net Income: 7,598M; EPS: 6.07; non-GAAP Net Income: 1,601M (+3.6%); non-GAAP EPS: 1.28 (+3.2%).

CF Ops: 3,926M (+23.5%).

Key product sales: Dupixent: 858M (+70%); Aubagio: 527M (+12.0%); Lantus: 693M (-7.0%); Toujeo: 239M (+10.0%); Lovenox: 301M (-9.2%); Plavix: 236M (-34.5%); Myozyme: 226M (-2.6%); Cerezyme: 179M (+2.1%); Fabrazyme: 199M (-5.7%).

2020 Guidance: Non-GAAP EPS: to grow between 6%-7% at CER from ~5% at CER.

Expected R&D milestones: U.S. regulatory decision for sutimlimab in Cold Agglutinin Disease in H2.

Flublok: EU regulatory decision for > 18-year old age group in H2.

Sarclisa: U.S. regulatory decision in Refractory Multiple Myeloma in H1 2021.

Baculovirus recombinant vaccine: Regulatory decision in COVID-19 in H1 2021.

MenQuadfi: EU regulatory decision for ≥ 12-month old age group in H1 2021.

https://seekingalpha.com/news/3596454-sanofi-q2-dupixent-sales-up-70-eps-guidance-revised-upward

Sanofi, Glaxo confirm 60M Covid vaccine dose deal with the U.K.

Following the release of its Q2 results, Sanofi (NASDAQ:SNY), as well as GlaxoSmithKline (NYSE:GSK), confirmed that they would supply the U.K. with up to 60M doses of their experimental coronavirus vaccine.

The two are also in talks to sell the shot to the U.S., the EU and global organizations, and plan to start a study compressing the early and middle stages of clinical tests in September. Sanofi reiterated that it’s targeting approval in the first half of 2021.

The companies are among dozens of others rushing to deliver a vaccine to help curb the coronavirus pandemic, while governments around the world jockey to secure doses in advance.

https://seekingalpha.com/news/3596461-sanofi-glaxo-confirm-60m-covid-vaccine-dose-deal-u-k

LivaNova PLC EPS beats by $0.15, beats on revenue

July 29, 2020

LivaNova PLC (NASDAQ:LIVN): Q2 Non-GAAP EPS of -$0.15 beats by $0.15; GAAP EPS of -$1.81 misses by $1.14.

Revenue of $182.2M (-34.3% Y/Y) beats by $12.46M.

Press Release

https://seekingalpha.com/news/3596471-livanova-plc-eps-beats-0_15-beats-on-revenue